R

Ribbskottet

Europe, Stockholms Lan, Sweden, Stockholm

Description

Ribbskottet is an investment company.

Investor Profile

Ribbskottet has backed more than 3 startups, with 2 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Convertible Note, Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in Sweden.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.

Stage Focus

  • Convertible Note (67%)
  • Post Ipo Equity (33%)

Country Focus

  • Sweden (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Hospital
  • Medical
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ribbskottet frequently co-invest with?

Co-Investments: 2
Karolinska
Europe, Stockholms Lan, Sweden, Solna
Co-Investments: 2

What are some of recent deals done by Ribbskottet?

Umecrine Cognition

Solna, Stockholms Lan, Sweden

Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders.

BiotechnologyHealth CarePharmaceutical
Convertible NoteJul 14, 2025
Amount Raised: $2,564,106
SciBase

Stockholm, Stockholms Lan, Sweden

SciBase is a medical technology company that develops devices for detection of malignant melanoma.

BiotechnologyHealth CareHospitalMedicalMedical Device
Post Ipo EquityJun 23, 2025
Amount Raised: $1,147,986
Umecrine Cognition

Solna, Stockholms Lan, Sweden

Umecrine Cognition has develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids.

BiotechnologyHealth CarePharmaceutical
Convertible NoteDec 19, 2024
Amount Raised: $2,157,497
Umecrine Cognition

Solna, Stockholms Lan, Sweden

Umecrine Cognition has develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids.

BiotechnologyHealth CarePharmaceutical
Convertible NoteNov 17, 2023
Amount Raised: $2,869,557